Dean Tang

List of Publications by Year
in descending order

137 papers	12,178 citations	23567 58 h-index	27406 106 g-index
143 all docs	143 docs citations	143 times ranked	15551 citing authors

#	Article	IF	Citations
1	The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature Medicine, 2011, 17, 211-215.	30.7	1,276
2	Side Population Is Enriched in Tumorigenic, Stem-Like Cancer Cells, whereas ABCG2+ and ABCG2âˆ’ Cancer Cells Are Similarly Tumorigenic. Cancer Research, 2005, 65, 6207-6219.	0.9	873
3	Understanding cancer stem cell heterogeneity and plasticity. Cell Research, 2012, 22, 457-472.	12.0	473
4	Hierarchical Organization of Prostate Cancer Cells in Xenograft Tumors: The CD44+Î±2Î²1+ Cell Population Is Enriched in Tumor-Initiating Cells. Cancer Research, 2007, 67, 6796-6805.	0.9	334
5	Functional Evidence that the Self-Renewal Gene <i>NANOG</i> Regulates Human Tumor Development. Stem Cells, 2009, 27, 993-1005.	3.2	307
6	The PSAâˆ’/lo Prostate Cancer Cell Population Harbors Self-Renewing Long-Term Tumor-Propagating Cells that Resist Castration. Cell Stem Cell, 2012, 10, 556-569.	11.1	281
7	Platelets and cancer metastasis: A causal relationship?. Cancer and Metastasis Reviews, 1992, 11, 325-351.	5.9	263
8	Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nature Protocols, 2017, 12, 439-451.	12.0	253
9	MicroRNA Regulation of Cancer Stem Cells. Cancer Research, 2011, 71, 5950-5954.	0.9	231
10	Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer and Metastasis Reviews, 1992, 11, 353-375.	5.9	214
11	Cancer stem cells and radioresistance. International Journal of Radiation Biology, 2014, 90, 615-621.	1.8	214
12	PC3 Human Prostate Carcinoma Cell Holoclones Contain Self-renewing Tumor-Initiating Cells. Cancer Research, 2008, 68, 1820-1825.	0.9	208
13	Cytosolic Accumulation of HSP60 during Apoptosis with or without Apparent Mitochondrial Release. Journal of Biological Chemistry, 2007, 282, 31289-31301.	3.4	207
14	Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Molecular Carcinogenesis, 2007, 46, 1-14.	2.7	201
15	12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer and Metastasis Reviews, 1994, 13, 365-396.	5.9	198
16	Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations. Cancer Research, 2015, 75, 4003-4011.	0.9	198
17	MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nature Communications, 2017, 8, 14270.	12.8	187
18	Early Mitochondrial Activation and Cytochrome c Up-regulation during Apoptosis. Journal of Biological Chemistry, 2002, 277, 50842-50854.	3.4	179

#	Article	IF	Citations
19	Concise Review: NANOG in Cancer Stem Cells and Tumor Development: An Update and Outstanding Questions. Stem Cells, 2015, 33, 2381-2390.	3.2	177
20	Distinct microRNA Expression Profiles in Prostate Cancer Stem/Progenitor Cells and Tumor-Suppressive Functions of let-7. Cancer Research, 2012, 72, 3393-3404.	0.9	172
21	Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer. Nature Communications, 2016, 7, 10798.	12.8	166
22	Evidence that Axon-Derived Neuregulin Promotes Oligodendrocyte Survival in the Developing Rat Optic Nerve. Neuron, 2000, 28, 81-90.	8.1	165
23	Target to apoptosis: A hopeful weapon for prostate cancer. , 1997, 32, 284-293.		158
24	Platelets and Cancer Metastasis: More Than an Epiphenomenon. Seminars in Thrombosis and Hemostasis, 1992, 18, 392-415.	2.7	140
25	Association of Active Caspase 8 with the Mitochondrial Membrane during Apoptosis: Potential Roles in Cleaving BAP31 and Caspase 3 and Mediating Mitochondrion-Endoplasmic Reticulum Cross Talk in Etoposide-Induced Cell Death. Molecular and Cellular Biology, 2004, 24, 6592-6607.	2.3	140
26	Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene, 2003, 22, 1475-1485.	5.9	132
27	miRNA-128 Suppresses Prostate Cancer by Inhibiting BMI-1 to Inhibit Tumor-Initiating Cells. Cancer Research, 2014, 74, 4183-4195.	0.9	128
28	Long-Term Culture of Purified Postnatal Oligodendrocyte Precursor Cells. Journal of Cell Biology, 2000, 148, 971-984.	5.2	126
29	Intracellular Nucleotides Act as Critical Prosurvival Factors by Binding to Cytochrome C and Inhibiting Apoptosome. Cell, 2006, 125, 1333-1346.	28.9	112
30	Thrombin increases the metastatic potential of tumor cells. International Journal of Cancer, 1993, 54, 793-806.	5.1	109
31	ATXN7L3 and ENY2 Coordinate Activity of Multiple H2B Deubiquitinases Important for Cellular Proliferation and Tumor Growth. Molecular Cell, 2016, 62, 558-571.	9.7	106
32	Mitochondrial ROS-derived PTEN oxidation activates PI3K pathway for mTOR-induced myogenic autophagy. Cell Death and Differentiation, 2018, 25, 1921-1937.	11.2	106
33	HORMONE-REFRACTORY PROSTATE CANCER CELLS EXPRESS FUNCTIONAL FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR). Journal of Urology, 1999, 161, 970-976.	0.4	104
34	Evidence That Arachidonate 15-Lipoxygenase 2 Is a Negative Cell Cycle Regulator in Normal Prostate Epithelial Cells. Journal of Biological Chemistry, 2002, 277, 16189-16201.	3.4	104
35	Apoptosis in the Absence of Cytochrome c Accumulation in the Cytosol. Biochemical and Biophysical Research Communications, 1998, 242, 380-384.	2.1	103
36	Fatty Acid Oxidation and Signaling in Apoptosis. Biological Chemistry, 2002, 383, 425-42.	2.5	103

#	Article	IF	Citations
37	The microRNA miR-34a Inhibits Non-Small Cell Lung Cancer (NSCLC) Growth and the CD44hi Stem-Like NSCLC Cells. PLoS ONE, 2014, 9, e90022.	2.5	102
38	Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Seminars in Cancer Biology, 2018, 52, 94-106.	9.6	100
39	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature Communications, 2018, 9, 3600.	12.8	96
40	Concise Review: Prostate Cancer Stem Cells: Current Understanding. Stem Cells, 2018, 36, 1457-1474.	3.2	90
41	Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS. Oncogene, 2005, 24, 2020-2031.	5.9	88
42	CD44-Positive Cancer Stem Cells Expressing Cellular Prion Protein Contribute to Metastatic Capacity in Colorectal Cancer. Cancer Research, 2013, 73, 2682-2694.	0.9	84
43	Bax-dependent Regulation of Bak by Voltage-dependent Anion Channel 2. Journal of Biological Chemistry, 2005, 280, 19051-19061.	3.4	83
44	Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nature Communications, 2020, 11, 2089.	12.8	83
45	Regulation of NANOG in cancer cells. Molecular Carcinogenesis, 2015, 54, 679-687.	2.7	79
46	Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 4505-4516.	7.0	78
47	Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein. EMBO Journal, 2001, 20, 5261-5268.	7.8	73
48	<scp>FAM</scp> 35A associates with <scp>REV</scp> 7 and modulates <scp>DNA</scp> Âdamage responses of normal and <scp>BRCA</scp> 1â€defective cells. EMBO Journal, 2018, 37, .	7.8	73
49	Thrombin enhances tumor cell adhesive and metastatic properties via increased Î±IIbÎ²3 expression on the cell surface. Thrombosis Research, 1992, 68, 233-245.	1.7	71
50	Cytotoxicity of Human Endogenous Retrovirus Kâ€“Specific T Cells toward Autologous Ovarian Cancer Cells. Clinical Cancer Research, 2015, 21, 471-483.	7.0	70
51	Cancer stem cells and cell size: A causal link?. Seminars in Cancer Biology, 2015, 35, 191-199.	9.6	69
52	Functional Remodeling of Benign Human Prostatic Tissues <i>In Vivo</i> by Spontaneously Immortalized Progenitor and Intermediate Cells. Stem Cells, 2010, 28, 344-356.	3.2	68
53	Bim, a Proapoptotic Protein, Up-regulated via Transcription Factor E2F1-dependent Mechanism, Functions as a Prosurvival Molecule in Cancer. Journal of Biological Chemistry, 2013, 288, 368-381.	3.4	68
54	Mitochondrially Localized Active Caspase-9 and Caspase-3 Result Mostly from Translocation from the Cytosol and Partly from Caspase-mediated Activation in the Organelle. Journal of Biological Chemistry, 2003, 278, 17408-17420.	3.4	67

#	Article	IF	Citations
55	MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic. Frontiers in Cell and Developmental Biology, 2021, 9, 640587.	3.7	67
56	Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. , 1999, 38, 118-125.		65
57	New insights into prostate cancer stem cells. Cell Cycle, 2013, 12, 579-586.	2.6	65
58	Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget, 2015, 6, 23959-23986.	1.8	65
59	Enhanced Endothelial Cell Retraction Mediated by 12(S)-HETE: A Proposed Mechanism for the Role of Platelets in Tumor Cell Metastasis. Experimental Cell Research, 1994, 210, 1-9.	2.6	64
60	Subcellular Localization and Tumor-suppressive Functions of 15-Lipoxygenase 2 (15-LOX2) and Its Splice Variants. Journal of Biological Chemistry, 2003, 278, 25091-25100.	3.4	61
61	Prostate cancer stem cells and their potential roles in metastasis. Journal of Surgical Oncology, 2011, 103, 558-562.	1.7	61
62	Suppression of W256 carcinosarcoma cell apoptosis by arachidonic acid and other polyunsaturated fatty acids. International Journal of Cancer, 1997, 72, 1078-1087.	5.1	56
63	Endothelial Cell Development, Vasculogenesis, Angiogenesis, and Tumor Neovascularization: An Update. Seminars in Thrombosis and Hemostasis, 2004, 30, 109-117.	2.7	54
64	Cellular determinants and microenvironmental regulation of prostate cancer metastasis. Seminars in Cancer Biology, 2017, 44, 83-97.	9.6	54
65	Prostate Luminal Progenitor Cells in Development and Cancer. Trends in Cancer, 2018, 4, 769-783.	7.4	54
66	Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis. Seminars in Cancer Biology, 2022, 78, 90-103.	9.6	53
67	The Lipoxygenase Metabolite, 12(S)-HETE, Induces a Protein Kinase C-Dependent Cytoskeletal Rearrangement and Retraction of Microvascular Endothelial Cells. Experimental Cell Research, 1993, 207, 361-375.	2.6	52
68	Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells. Oncogene, 2005, 24, 3583-3595.	5.9	52
69	Fatty acid modulation of tumor cell-platelet-vessel wall interaction. Cancer and Metastasis Reviews, 1992, 11, 389-409.	5.9	51
70	15-Lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins and Other Lipid Mediators, 2007, 82, 135-146.	1.9	50
71	Apoptosis: A current molecular analysis. Pathology and Oncology Research, 1996, 2, 117-131.	1.9	49
72	Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance. Cancer Letters, 2021, 518, 1-9.	7.2	49

#	Article	IF	Citations
73	Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications. Endocrine-Related Cancer, 2015, 22, T209-T220.	3.1	48
74	miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells. Oncotarget, 2016, 7, 56628-56642.	1.8	48
75	Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms. PLoS ONE, 2011, 6, e24397.	2.5	47
76	ATG5 cancer mutations and alternative mRNA splicing reveal a conjugation switch that regulates ATG12â€“ATG5-ATG16L1 complex assembly and autophagy. Cell Discovery, 2019, 5, 42.	6.7	44
77	Prostacyclin and its analogues: antimetastatic effects and mechanisms of action. Cancer and Metastasis Reviews, 1994, 13, 349-364.	5.9	43
78	Studies on the role of platelet eicosanoid metabolism and integrin Î±IIbÎ²3 in tumor-cell-induced platelet aggregation. International Journal of Cancer, 1993, 54, 92-101.	5.1	41
79	NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell Discovery, 2016, 2, 16041.	6.7	41
80	Tumor Dormancy and Slow-Cycling Cancer Cells. Advances in Experimental Medicine and Biology, 2019, 1164, 199-206.	1.6	41
81	Systematic evaluation of RNA-Seq preparation protocol performance. BMC Genomics, 2019, 20, 571.	2.8	38
82	Evidence that senescent human prostate epithelial cells enhance tumorigenicity: Cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. International Journal of Cancer, 2008, 122, 1483-1495.	5.1	37
83	Numbâˆ’/low Enriches a Castration-Resistant Prostate Cancer Cell Subpopulation Associated with Enhanced Notch and Hedgehog Signaling. Clinical Cancer Research, 2017, 23, 6744-6756.	7.0	36
84	Histone 2B-GFP Label-Retaining Prostate Luminal Cells Possess Progenitor Cell Properties and Are Intrinsically Resistant to Castration. Stem Cell Reports, 2018, 10, 228-242.	4.8	36
85	Reduced 15S-Lipoxygenase-2 Expression in Esophageal Cancer Specimens and Cells and Upregulation In Vitro by the Cyclooxygenase-2 Inhibitor, NS398. Neoplasia, 2003, 5, 121-127.	5.3	34
86	Methodologies in Assaying Prostate Cancer Stem Cells. Methods in Molecular Biology, 2009, 568, 85-138.	0.9	34
87	A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	34
88	Critical and Distinct Roles of p16 and Telomerase in Regulating the Proliferative Life Span of Normal Human Prostate Epithelial Progenitor Cells. Journal of Biological Chemistry, 2008, 283, 27957-27972.	3.4	32
89	Understanding and targeting prostate cancer cell heterogeneity and plasticity. Seminars in Cancer Biology, 2022, 82, 68-93.	9.6	31
90	In vivo functional studies of tumor-specific retrogene NanogP8 in transgenic animals. Cell Cycle, 2013, 12, 2395-2408.	2.6	30

#	Article	IF	Citations
91	Usp22 controls multiple signaling pathways that are essential for vasculature formation in the mouse placenta. Development (Cambridge), 2019, 146, .	2.5	30
92	Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK). Journal of Cellular Physiology, 1995, 165, 291-306.	4.1	29
93	Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. Oncogene, 2004, 23, 6942-6953.	5.9	27
94	Activated ERM Protein Plays a Critical Role in Drug Resistance of MOLT4 Cells Induced by CCL25. PLoS ONE, 2013, 8, e52384.	2.5	27
95	Generation of a C57BL/6<i>MYC</i>-Driven Mouse Model and Cell Line of Prostate Cancer. Prostate, 2016, 76, 1192-1202.	2.3	27
96	12(S)-hydroxyeicosatetraenoic acid increases the actin microfilament content in B16a melanoma cells: A protein kinase-dependent process. , 1998, 77, 271-278.		25
97	Tumor-suppressive functions of 15-Lipoxygenase-2 and RB1CC1 in prostate cancer. Cell Cycle, 2014, 13, 1798-1810.	2.6	22
98	Cyclophilin B induces chemoresistance by degrading wildâ€type p53 via interaction with MDM2 in colorectal cancer. Journal of Pathology, 2018, 246, 115-126.	4.5	21
99	A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60. Journal of Clinical Investigation, 2022, 132, .	8.2	21
100	BMD188, A novel hydroxamic acid compound, demonstrates potent anti-prostate cancer effectsin vitro andin vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases. Pathology and Oncology Research, 1998, 4, 179-190.	1.9	20
101	Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors that Can Function as a Cell of Origin for Prostate Cancer. Stem Cells Translational Medicine, 2017, 6, 748-760.	3.3	19
102	Molecular determinants of prostate cancer metastasis. Oncotarget, 2017, 8, 88211-88231.	1.8	19
103	Phenotypic properties of cultured tumor cells: Integrin Î±IIbÎ²3 expression, tumor-cell-induced platelet aggregation, and tumor-cell adhesion to endothelium as important parameters of experimental metastasis. International Journal of Cancer, 1993, 54, 338-347.	5.1	18
104	Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSAâˆ’/lo castration-resistant cells. Oncotarget, 2016, 7, 14220-14240.	1.8	17
105	Role of Protein Kinase C and Phosphatases in 12(S)-Hete-Induced Tumor Cell Cytoskeletal Reorganization. Advances in Experimental Medicine and Biology, 1997, 400A, 349-361.	1.6	16
106	LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor. Seminars in Cancer Biology, 2022, 82, 120-133.	9.6	14
107	LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer. Nature Communications, 2019, 10, 5494.	12.8	13
108	Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. RNA Biology, 2021, 18, 722-729.	3.1	13

#	Article	IF	Citations
109	Hemostasis and malignancy: an overview. Cancer and Metastasis Reviews, 1992, 11, 223-226.	5.9	12
110	Detection of Apoptosis in Cell-Free Systems. Methods in Molecular Biology, 2009, 559, 65-75.	0.9	12
111	Dissociated Primary Human Prostate Cancer Cells Coinjected with the Immortalized Hs5 Bone Marrow Stromal Cells Generate Undifferentiated Tumors in NOD/SCID-Î³ Mice. PLoS ONE, 2013, 8, e56903.	2.5	12
112	Nanog1 in NTERA-2 and Recombinant NanogP8 from Somatic Cancer Cells Adopt Multiple Protein Conformations and Migrate at Multiple M.W Species. PLoS ONE, 2014, 9, e90615.	2.5	11
113	Defective Molecular Timer in the Absence of Nucleotides Leads to Inefficient Caspase Activation. PLoS ONE, 2011, 6, e16379.	2.5	11
114	Prostate Cancer Old Problems and New Approaches. Pathology and Oncology Research, 1996, 2, 191-211.	1.9	10
115	Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.3	10
116	Evidence for context-dependent functions of KDM5B in prostate development and prostate cancer. Oncotarget, 2020, 11, 4243-4252.	1.8	10
117	Critical Role of Arachidonate Lipoxygenases in Regulating Apoptosis. Advances in Experimental Medicine and Biology, 1997, 407, 405-411.	1.6	8
118	Cancer stem cells: advances in biology and clinical translationâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2021, 1506, 142-163.	3.8	8
119	An Old Player on a New Playground: Bmi-1 as a Regulator of Prostate Stem Cells. Cell Stem Cell, 2010, 7, 639-640.	11.1	7
120	Target to apoptosis: A hopeful weapon for prostate cancer. Prostate, 1997, 32, 284-293.	2.3	7
121	Actin cleavage in various tumor cells is not a critical requirement for executing apoptosis. Pathology and Oncology Research, 1998, 4, 135-145.	1.9	6
122	Cancer cell heterogeneity and plasticity: From molecular understanding to therapeutic targeting. Seminars in Cancer Biology, 2022, 82, 1-2.	9.6	5
123	Abnormal differentiation, hyperplasia and embryonic/perinatal lethality in BK5-T/t transgenic mice. Differentiation, 2009, 77, 324-334.	1.9	4
124	â€œSpliceâ€•a way towards neuroendocrine prostate cancer. EBioMedicine, 2018, 35, 12-13.	6.1	4
125	Transgenic overexpression of NanogP8 in the mouse prostate is insufficient to initiate tumorigenesis but weakly promotes tumor development in the Hi-Myc mouse model. Oncotarget, 2017, 8, 52746-52760.	1.8	4
126	Cancers of the breast and prostate: a stem cell perspective. Endocrine-Related Cancer, 2015, 22, E9-E11.	3.1	3

#	Article	IF	Citations
127	Prostate cancer old problems and new approaches. Pathology and Oncology Research, 1996, 2, 98-109.	1.9	2
128	Prostate cancer old problems and new approaches. Pathology and Oncology Research, 1996, 2, 276-292.	1.9	2
129	CD44 as a Functional Cancer Stem Cell Marker and a Potential Therapeutic Target. , 2007, , 317-334.		1
130	Tyrosine phosphorylation of a â^¼30 kd protein precedes Î±vÎ²3 integrin-signaled endothelial cell spreading and motility on matrix proteins. Pathology and Oncology Research, 1996, 2, 21-29.	1.9	0
131	Prostate cancer stem cells. , 0, , 15-30.		0
132	Deep RNA-Seq analysis reveals unexpected features of human prostate basal epithelial cells. Genomics Data, 2016, 7, 318-320.	1.3	0
133	Prostate Cancer Stem Cells and Their Involvement in Metastasis. , 2009, , 455-461.		0
134	Cancer Stem Cells: Potential Mediators of Therapeutic Resistance and Novel Targets of Anti-cancer Treatments. , 2009, , 559-579.		0
135	Abstract 132: MicroRNA expression profiling in tumorigenic prostate cancer cells and tumor suppressive functions of let-7. , 2012, , .		0
136	Prostate Cancer Stem Cells: A Brief Review. , 2013, , 37-49.		0
137	Dual Regulatory Role of Cyclooxygenase and Lipoxygenase and their Products in Cell Survival and Apoptosis. , 1996, , 133-139.		0